Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Advanced Technologies for Antigen Identification
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Advanced Technologies for Antigen Identification
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses

Samantha K. Greaney, Alain P. Algazi, Katy K. Tsai, Kathryn T. Takamura, Lawrence Chen, Christopher G. Twitty, Li Zhang, Alan Paciorek, Robert H. Pierce, Mai H. Le, Adil I. Daud and Lawrence Fong
Samantha K. Greaney
1Division of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Samantha K. Greaney
Alain P. Algazi
1Division of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katy K. Tsai
1Division of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn T. Takamura
3OncoSec Medical Incorporated, San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Chen
1Division of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher G. Twitty
3OncoSec Medical Incorporated, San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Zhang
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Paciorek
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert H. Pierce
3OncoSec Medical Incorporated, San Diego, California.
4University of Washington, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert H. Pierce
Mai H. Le
3OncoSec Medical Incorporated, San Diego, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adil I. Daud
1Division of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adil I. Daud
  • For correspondence: Lawrence.Fong@ucsf.edu adil.daud@ucsf.edu
Lawrence Fong
1Division of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Lawrence.Fong@ucsf.edu adil.daud@ucsf.edu
DOI: 10.1158/2326-6066.CIR-19-0359 Published February 2020
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: December 2019 to April 2021

AbstractFull-text HTMLPDF
Total9491403872

Cited By

Article Information

Volume 8, Issue 2, pp. 246-254

DOI 
https://doi.org/10.1158/2326-6066.CIR-19-0359
PubMed 
31852717

Published By 
American Association for Cancer Research
Print ISSN 
2326-6066
Online ISSN 
2326-6074
History 
  • Received May 15, 2019
  • Revision received August 26, 2019
  • Accepted December 9, 2019
  • Published first December 18, 2019.

Article Versions

  • Previous version (December 18, 2019 - 08:14).
  • Previous version (January 14, 2020 - 06:05).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2019 American Association for Cancer Research.

Author Information

  1. Samantha K. Greaney1,
  2. Alain P. Algazi1,2,
  3. Katy K. Tsai1,2,
  4. Kathryn T. Takamura3,
  5. Lawrence Chen1,
  6. Christopher G. Twitty3,
  7. Li Zhang2,
  8. Alan Paciorek2,
  9. Robert H. Pierce3,4,
  10. Mai H. Le3,
  11. Adil I. Daud1,2,*, and
  12. Lawrence Fong1,2,*
  1. 1Division of Hematology and Oncology, University of California, San Francisco, San Francisco, California.
  2. 2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  3. 3OncoSec Medical Incorporated, San Diego, California.
  4. 4University of Washington, Seattle, Washington.
  1. ↵*Corresponding Authors:
    Lawrence Fong, University of California, San Francisco, 513 Parnassus Avenue, Room HSE301A, San Francisco, CA 94143-0519. Phone: 415-514-3160; Fax: 415-476-0459; E-mail: Lawrence.Fong{at}ucsf.edu; and Adil I. Daud, University of California, San Francisco, 550 16th Street, Room MS6809, San Francisco, CA 94158. E-mail: adil.daud{at}ucsf.edu
View Full Text
PreviousNext
Back to top
Cancer Immunology Research: 8 (2)
February 2020
Volume 8, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses
Samantha K. Greaney, Alain P. Algazi, Katy K. Tsai, Kathryn T. Takamura, Lawrence Chen, Christopher G. Twitty, Li Zhang, Alan Paciorek, Robert H. Pierce, Mai H. Le, Adil I. Daud and Lawrence Fong
Cancer Immunol Res February 1 2020 (8) (2) 246-254; DOI: 10.1158/2326-6066.CIR-19-0359

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses
Samantha K. Greaney, Alain P. Algazi, Katy K. Tsai, Kathryn T. Takamura, Lawrence Chen, Christopher G. Twitty, Li Zhang, Alan Paciorek, Robert H. Pierce, Mai H. Le, Adil I. Daud and Lawrence Fong
Cancer Immunol Res February 1 2020 (8) (2) 246-254; DOI: 10.1158/2326-6066.CIR-19-0359
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Modified HIF in CD8+ T Cells Increases Antitumor Efficacy
  • Combined Arginase and Immunotherapy Controls Tumor Growth
  • Overcoming Resistance to PD-L1 Therapy by Targeting PIM1
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement